KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) EBIT Margin (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed EBIT Margin for 7 consecutive years, with 50.6% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 5699.0% year-over-year to 50.6%, compared with a TTM value of 14.95% through Dec 2025, down 142.0%, and an annual FY2025 reading of 14.95%, down 142.0% over the prior year.
  • EBIT Margin was 50.6% for Q4 2025 at Esperion Therapeutics, up from 11.41% in the prior quarter.
  • Across five years, EBIT Margin topped out at 52.47% in Q1 2024 and bottomed at 1038.15% in Q1 2021.
  • Average EBIT Margin over 5 years is 167.06%, with a median of 106.21% recorded in 2023.
  • The sharpest move saw EBIT Margin soared 300782bps in 2021, then tumbled -19798bps in 2022.
  • Year by year, EBIT Margin stood at 361.2% in 2021, then soared by 37bps to 225.92% in 2022, then soared by 42bps to 131.37% in 2023, then soared by 95bps to 6.4% in 2024, then skyrocketed by 891bps to 50.6% in 2025.
  • Business Quant data shows EBIT Margin for ESPR at 50.6% in Q4 2025, 11.41% in Q3 2025, and 8.61% in Q2 2025.